




Patent N° FR 0210810

# LUMISKIN™



## **Diacetyl boldine**

### **Function:**

Skin lightening

### **Definition:**

Diacetyl Boldine (DAB)  
In C<sub>8</sub> C<sub>10</sub> triglycerides

### **Properties:**

Diacetyl Boldine (DAB) works via  
 $\alpha$ -adrenergic antagonist receptors  
and calcium flow regulation

### **Point of interest:**

Tyrosinase is not directly inhibited  
by competition, tyrosinase is  
stabilised in its inactive form

### **INCI name:**

Caprylic/Capric Triglyceride  
- Diacetyl Boldine

### **Applications:**


Emulsions, soaps, make-up  
products with lightening or  
whitening properties

### **Formulation:**




Oil soluble

### **Recommended use level:**

4%



LUMISKIN™



LUMISKIN™



Sederma - member of Croda International Group

[www.sederma.fr](http://www.sederma.fr)

E-mail: [sederma@sederma.fr](mailto:sederma@sederma.fr)



## In vitro tests

### ● Test on melanocyte B16 lines with 4% Lumiskin™

Inhibition of tyrosinase activity:	53%
Decrease in melanin quantity:	70%

### ● Test on human melanocytes with 4% Lumiskin™

Decrease in melanin synthesis:	51%
--------------------------------	-----

## Ex vivo test

### ● Skin Ethic® 3D model of epidermis type VI with 4% Lumiskin™

Visible and significant decrease of the epidermic pigmentation

## In vivo tests on Asian volunteers

### ● Colorimetric test

Study on 20 Asian volunteers.

Twice daily application of a cream containing 4% Lumiskin™ (40 ppm DAB) for 2 months.


Measurement of ITA° (clarity) by chromameter and **Melanin Index** by mexameter on one homogeneous area (two sites), one hyperpigmented area and one untreated zone (chin)

### ● Self-Evaluation

Lightening of the skin	+ 71%
Lessening of the hyperpigmented areas	+ 54%
Complexion more even	+ 65%
Skin more radiant	+ 74%

## In vitro

### Effect on melanin production



The efficacy of DAB (Diacetyl Boldine) on melanogenesis is visible to the naked eye


**DAB is up to 30 times more active than Kojic acid**

## Ex vivo

### Control



### Lumiskin™ 4%



## In vivo

### Colorimetric test

Melanin index	zones	Normal	Hyper-pigmentation	Control
Variation (D56-D0)		-17 <sup>(1)</sup>	-20 <sup>(1)</sup>	-6 <sup>(ns)</sup>
Maximum variation		-25%	-18%	ns
Volunteers with improvement		85%	90%	50%

ITA° (clarity)	zones	Normal	Hyper-pigmentation	Control
Variation (D56-D0)		+2° <sup>(3)</sup>	+2.9° <sup>(2)</sup>	+1.2° <sup>(ns)</sup>
Maximum variation		+11.2°	+9.6°	ns
Volunteers with improvement		65%	80%	50%

(1) highly significant/D0: p<<0.01 ; (2) significant/D0: p<0.01 ; (3) significant/D0: p<0.05 ; ns: non significant

## In vivo tests on age spots

### ● Colorimetric test

Test on 22 caucasian volunteers aged 58 +/- 7.8.

Twice daily application of a cream containing 4% Lumiskin™ (40 ppm DAB) for 2 months (between October and December) on one hand versus the other hand.

Measurement of **Melanin Index** by mexameter on 4 sites.

Melanin index	Treated hand	Control hand
Variation (D56-D0)	- 40	- 25
Variation (%) (Control J56/Treated J56)	23.4%*	

\* significant/Control : P<0,05

## In vivo

### Colorimetric test

#### Before

#### After 2 months

